Frontlight ResearchEarly access
CompletedPhase 4
Optimization of Vonoprazan-based Dual Therapy for Helicobacter Pylori
Key facts
- Who runs it
- Nanjing First Hospital, Nanjing Medical University
- Where
- China13 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 4
- People taking part
- 900 people enrolled
- Started
- 20 Jan 2023
- Ended
- 5 Nov 2024
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Vonoprazan
- Amoxicillin
- Record updated
- 19 November 2024
Who can take part
- Age
- 18 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Ages between 18 and 70 years; Sexes eligible for study: both
- patients who are diagnosed with Helicobacter pylori with 13C urea breath test or 14C urea breath test
- treatment-naive patients or patients who failed to eradicate Helicobacter pylori in the past but haven't undergone eradication therapy in the past six months
- voluntary to be involved in the study and written informed consent was obtained from all patients
Who cannot take part
- patients who underwent eradication therapy for Helicobacter pylori during the last six months
- patients who are taking glucocorticoids, non-steroidal anti-inflammatory drugs or anticoagulants
- patients who have severe concurrent diseases such as hepatic,cardiovascular,respiratory,renal disorders or malignancies
- allergic reactions to the study drugs
- patients with peptic ulcer
- patients who have history of esophageal or gastric surgery
- MALT lymphoma of stomach or malignant tumor
- patients who took antibiotics,bismuth agents,probiotics within four weeks prior to treatment and those who took H2 receptor antagonists,proton pump inhibitors(PPIs) or potassium competitive acid blockers within two weeks prior to treatment
- pregnant or lactating women
- Alcohol abusers
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The purpose of this study was to evaluate the efficacy and safety of vonoprazan with different doses of amoxicillin for Helicobacter Pylori.
The 3 groups in the trial
- high dose amoxicillin with vonoprazan groupExisting treatment, for comparison
vonoprazan 20mg bid and amoxicillin 1000mg tid for 14 days
Treatment: Vonoprazan and Amoxicillin
- standard dose amoxicillin with vonoprazan groupTreatment being tested
vonoprazan 20mg bid and amoxicillin 1000mg bid for 14 days
Treatment: Vonoprazan and Amoxicillin
- low dose amoxicillin with vonoprazan groupTreatment being tested
vonoprazan 20mg bid and amoxicillin 500mg tid for 14 days
Treatment: Vonoprazan and Amoxicillin
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Optimization of Vonoprazan-based Dual Therapy for Helicobacter Pylori:a Prospective, Multicenter, Open Label, Randomized Controlled Study:
- Publications
- Record updated
- 19 November 2024